AMRN Amarin Corp - ADR

$AMRN 🚨 MAJOR FRANCE DEVELOPMENT: VAZKEPA ENTERS OFFICIAL REIMBURSEMENT REVIEW 🚨 🎙️ JULY 29 Q2 CALL: Aaron Berg on France: “we have confidence in our partner to be able to do something there”, but said there was no update & cautioned it’s a lengthy process. 📅 OCT 7: France’s HAS Transparency Commission listed VAZKEPA for “EXAMENS: INSCRIPTION.” 🔎 INSCRIPTION = review for potential inclusion on France’s reimbursable medicines list. 🔥 TIMELINE: ✅ June 2025: Amarin identified revised France/Germany resubmission strategies. ✅ July 2026: Berg highlighted France and Recordati’s potential. ✅ October 2026: Official HAS examination agenda. ⏳ NEXT: HAS opinion (possibly Nov to Jan) ➡️ CEPS price talks ➡️ reimbursement listing ➡️ launch (2027 possible, not guaranteed). ⚠️ HAS gave a restricted favorable opinion in 2021, but France never launched. France is one of Amarin’s last ✌️ top 5 EU market left to open. AS ALWAYS, YOUR WELCOME 🫡

$AMRN FYI, I just got a response from Mark Hull on EMT2: "I will be presenting the results at the ESMO 2026 Congress in Madrid, Spain on Sunday October 25th. I understand that the Abstract (a short written summary) will be available in a supplement to the Annals of Oncology journal approximately two weeks later."

$AMRN 🚨 AMARIN IN RARE COMPANY AT ESMO 2026 — AND THE LR-EtEPA ANGLE 🚨 1️⃣ LBA30 — AMARIN / EMT2 2️⃣ LBA32 — BMS / CheckMate 8HW 3️⃣ LBA48 — ASTRAZENECA / EMERALD-3 4️⃣ LBA87 — GSK / AZUR-1 EMT2 is a late-breaking colorectal cancer study being presented alongside major oncology programs from BMS, AstraZeneca & GSK. 👀 A positive EMT2 readout could mean Phase 3 human evidence for EPA in colorectal liver metastasis recurrence. 🚨 NOW LOOK AT THE ATTACHED LR-EtEPA PATENT DRAWING. Fig. 20 shows LR-EtEPA produced more EPA relative to AA in several LIVER cell-membrane phospholipids than plain EtEPA after only 7 days. 💡 In one membrane phospholipid, the EPA/AA ratio was 82% HIGHER That does NOT prove tumor exposure or cancer efficacy. But the connection is striking: 🧬 EMT2 could expand what EPA biology is worth. 🔐 LR-EtEPA could be the protected product platform built to capture that value.

$AMRN $AMRN — EMT-2 COUNTDOWN 🚨 Big clarity on EMT-2: • Mark Hull confirmed he will present the Phase 3 EMT-2 results at ESMO 2026 on Oct. 25 in Madrid. • EMT-2 is officially LBA30 — Late-Breaking Abstract: EPA vs placebo after resection of colorectal cancer liver metastases. • This is the definitive Phase 3 readout, not an interim analysis. • No verified efficacy numbers have leaked—no HR, P-value, PFS or OS yet. • LBA30 is embargoed until the ESMO release. Oct. 25 is the date circled. • LBA status does NOT prove a positive result—but it confirms ESMO accepted the mature Phase 3 findings for late-breaking presentation. Bottom line: The wait is almost over. EMT-2 = LBA30. Oct. 25. 🎯

Why I still think $AMRN is a good strategic fit for $NOV: “Novo’s own words from CMD yesterday make the strategic case for something like AMRN/Vascepa pretty clear: • ‘We will be more active within business development… [we] have gone shopping’ • Looking to fill gaps in CVD / residual risk areas • Quality of asset first, size second • Disciplined bolt-ons in cardiometabolic adjacencies Approved 25% MACE RRR product that sits perfectly in residual risk + Novo’s new CVD push + tiny market cap = logical opportunistic fit.

$AMRN — EMT-2 could be a major inflection point AMRN has fallen roughly 14% from its September high, yet the company’s reported cash + short-term investments were about $315M as of June 30. At ~$12.35, the market cap is only about $261M. If EMT-2 delivers spectacularly positive results, the story could shift from simply recovering the recent decline to a broader reassessment of icosapent ethyl’s value—potentially adding a significant oncology opportunity to the existing cardiovascular franchise. This poster lays out the math behind $15, $20, $25 and $30 scenarios. These are illustrative valuation scenarios—not price targets or predictions.

$AMRN AMRN/HIKMA UPDATE: ⚖️ ANOTHER DEADLINE EXTENSION — FULL SCOTUS-TO-NOW TIMELINE The Hikma litigation has now been sitting in a post-SCOTUS holding pattern for nearly four months: 📌 Jan. 16: SCOTUS grants Hikma’s petition 📌 Apr. 29: Oral arguments 📌 June 4: Supreme Court unanimously reverses the Federal Circuit and remands for further proceedings 📌 July 6: Supreme Court judgment formally issued 📌 July 16: Delaware court orders Amarin/Hikma to file a Joint Status Report by July 30 📌 July 31: Deadline extended → Sept. 1 📌 Sept. 1: Deadline extended again → Oct. 1 📌 Oct. 1: Parties jointly request another extension → Oct. 15 The repeated extensions don’t tell us why — but after nearly four months, they make the next joint filing increasingly important. Oct. 15 could finally provide the first real indication of what comes next: resumed litigation, a negotiated resolution, or more time ⏳

$AMRN Phase 3 EMT2 results drop Oct 25 at ESMO, as a late-breaker. ~$290M market cap, with a potential cancer indication on deck. Earnings follow Oct 28. Two catalysts in four days. Watching closely. 👀

$AMRN fyi The EMT2 result has apparently been assigned LBA87, meaning it is being handled as a late-breaking abstract at ESMO 2026. A late-breaking designation is used for new research findings considered sufficiently important/timely for the conference program.

$AMRN If i ever get out of here i can promise you one thing. Its the last Bio stock i ever buy..

$AMRN $14.9/sh is what it's worth on CASH on hand alone. That's not counting any +ve EPS surprise that could materialize 👍☘️💎

$AMRN In the past, this stock has frequently rallied off of extreme oversold levels represented by an RSI < 25 (green boxes). The last time this indicator bottomed out, it rallied up +50%. That same development is occurring marked, by the RSI indicator finally turning up from this deep trough this week. If this repetitive pattern sparks the expected rally, a longer term inverted head and shoulders pattern will confirm -- a popular setup that will flash on shorty's scans - - leading to short covering.

$AMRN Rough day, I get it. But zoom out from the ticker for a second: ✅ Q2 showed global volume growth and lower operating expenses ✅ Management is guiding to positive cash flow for full-year 2026 ✅ Trading below book value, at a market cap under $300M ✅ Fully partnered international model is starting to work ✅ Supreme Court "skinny label" case could matter a lot for generic competition ✅ Q3 earnings Oct 30, and they've beaten EPS estimates the last several quarters 52-week lows are where patience gets tested. I'm holding. Not advice, do your own DD. 💪

$AMRN I know it a long time ago, now its getting real. Let retail jump schip and sell big later. Big boys playing. I exspect zero profit so i can sít this BS out until the end. Call me stuborn and stupid, i dont care. GL all.

$AMRN Hey NVO, why not BO BIC Vascepa for your CVD risk reduction business. It's primed for rapid sales growth in EU with an IP protection lasting up to 2039. Plus, AMRN Would be an easy bolt-on while diversifying your obesity/T2DM franchise. 👍☘️💎

$AMRN Sarrisa still unlocking the value of this asset with all their expertise? 😂. Alex fkd up knocking that chick up and divorce - AUM crashed, huge losses on the books - rename it Sarissa Asset Mismanagement. What a waste.

$AMRN Big thanks to Jroon and Capbeer for there inputs here.. Hopefully we get all get to see a pot of gold at the end of this rambow.

$AMRN Going down down … looks like a free fall… no indication for a reversal at this moment!! Why?? God bless Longs …

$AMRN I really won’t mind if EMT2 is a nothing burger. It can be as broad as , it did not have any negative effect. It had some positive effect but no where close to statistically significant. But what we cannot afford is failure to get LR Et-EPA patent. I hope this down trend is not because someone knows something about the possibility of the Patent.

$AMRN One of Wyckoff’s most practical ideas is the Spring pattern. It happens like this: Price dips below support. Traders watching that support level often panic and sell, thinking the market has broken down. The breakdown does not hold. Instead of collapsing further, price quickly pops back above support. The range continues. Price settles back into the trading range and often begins climbing higher. This “spring” below support is essentially a test. If sellers cannot push the market lower, it means supply has been absorbed. Buyers quietly step in, and the path upward opens.